Evaxion Biotech

About:

Evaxion Biotech is devoted to the discovery and development of vaccines against cancer and infectious diseases.

Website: http://evaxion-biotech.com/

Top Investors: National Institutes of Health, Lincoln Park Capital Fund, Merck Global Health Innovation Fund, Negma Group, City of Rahway

Description:

Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus) induced skin and soft tissue infections.